Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity

Journal of Experimental Medicine

Volumn 212, Issue 10, 2015, Pages 1603-1621

  Paterson, Alison M ^a,b   Lovitch, Scott B ^a,b   Sage, Peter T ^a,b   Juneja, Vikram R ^a,b   Lee, Youjin ^b   Trombley, Justin D ^a,b   Arancibia Cárcamo, Carolina V ^c   Sobel, Raymond A ^d   Rudensky, Alexander Y ^e   Kuchroo, Vijay K ^b   Freeman, Gordon J ^f   Sharpe, Arlene H ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d STANFORD UNIVERSITY   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; IL10 PROTEIN, MOUSE; TAMOXIFEN;

ADULT; ADULTHOOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GENE DELETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; AGE; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; DISEASE RESISTANCE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; TRANSGENIC MOUSE;

AGE FACTORS; AMINO ACID SEQUENCE; ANIMALS; AUTOIMMUNITY; CTLA-4 ANTIGEN; DISEASE RESISTANCE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE DELETION; INTERLEUKIN-10; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, REGULATORY; TAMOXIFEN;

EID: 84949673235     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20141030     Document Type: Article

References (81)

1. Allard, B., S. Pommey, M.J. Smyth, and J. Stagg. 2013. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer Res. 19: 5626-5635. http://dx.doi.org/10.1158/1078-0432.CCR-13-0545
2. Asano, M., M. Toda, N. Sakaguchi, and S. Sakaguchi. 1996. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184: 387-396. http://dx.doi.org/10.1084/ jem.184.2.387
3. Bachmann, M.F., G. Köhler, B. Ecabert, T.W. Mak, and M. Kopf. 1999. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J. Immunol. 163:1128-1131.
4. Bettelli, E., M.P. Das, E.D. Howard, H.L. Weiner, R.A. Sobel, and V.K. Kuchroo. 1998. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol. 161:3299-3306.
5. Bettelli, E., M. Pagany, H.L. Weiner, C. Linington, R.A. Sobel, and V.K. Kuchroo. 2003. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med. 197: 1073-1081. http://dx.doi.org/10.1084/jem.20021603
6. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T.B. Strom, M. Oukka, H.L. Weiner, and V.K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 441: 235-238. http://dx.doi.org/10.1038/nature04753
7. Buhlmann, J.E., S.K. Elkin, and A.H. Sharpe. 2003. A role for the B7-1/ B7-2:CD28/CTLA-4 pathway during negative selection. J. Immunol. 170: 5421-5428. http://dx.doi.org/10.4049/jimmunol.170.11.5421
8. Bulliard, Y., R. Jolicoeur, M. Windman, S.M. Rue, S. Ettenberg, D.A. Knee, N.S. Wilson, G. Dranoff, and J.L. Brogdon. 2013. Activating Fc Υ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210: 1685-1693. http://dx .doi.org/10.1084/jem.20130573
9. Chambers, C.A., D. Cado, T. Truong, and J.P. Allison. 1997. Thymocyte development is normal in CTLA-4-deficient mice. Proc. Natl. Acad. Sci. USA. 94: 9296-9301. http://dx.doi.org/10.1073/pnas.94.17.9296
10. Chang, T.T., R.A. Sobel, T. Wei, R.M. Ransohoff, V.K. Kuchroo, and A.H. Sharpe. 2003. Recovery from EAE is associated with decreased survival of encephalitogenic T cells in the CNS of B7-1/B7-2-deficient mice. Eur. J. Immunol. 33: 2022-2032. http://dx.doi.org/10.1002/eji.200323180
11. Chuang, E., K.M. Lee, M.D. Robbins, J.M. Duerr, M.L. Alegre, J.E. Hambor, M.J. Neveu, J.A. Bluestone, and C.B. Thompson. 1999. Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases. J. Immunol. 162:1270-1277.
12. Chuang, E., T.S. Fisher, R.W. Morgan, M.D. Robbins, J.M. Duerr, M.G. Vander Heiden, J.P. Gardner, J.E. Hambor, M.J. Neveu, and C.B. Thompson. 2000. The CD28 and CTLA-4 receptors associate with the serine/ threonine phosphatase PP2A. Immunity. 13: 313-322. http://dx.doi.org/ 10.1016/S1074-7613(00)00031-5
13. Cilio, C.M., M.R. Daws, A. Malashicheva, C.L. Sentman, and D. Holmberg. 1998. Cytotoxic T lymphocyte antigen 4 is induced in the thymus upon in vivo activation and its blockade prevents anti-CD3-mediated depletion of thymocytes. J. Exp. Med. 188: 1239-1246. http://dx.doi .org/10.1084/jem.188.7.1239
14. + T cells. Proc. Natl. Acad. Sci. USA. 101: 14473-14478. http://dx.doi.org/10.1073/pnas.0403303101
15. Fallarino, F., U. Grohmann, K.W. Hwang, C. Orabona, C. Vacca, R. Bianchi, M.L. Belladonna, M.C. Fioretti, M.L. Alegre, and P. Puccetti. 2003. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4: 1206-1212. http://dx.doi.org/10.1038/ni1003
16. Fife, B.T., and J.A. Bluestone. 2008. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 224: 166-182. http://dx.doi.org/10.1111/j.1600-065X.2008.00662.x
17. Fraser, J.H., M. Rincón, K.D. McCoy, and G. Le Gros. 1999. CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells. Eur. J. Immunol. 29: 838-844. http://dx.doi.org/10.1002/(SICI)1521-4141(199903)29:03<838:AID-IMMU838>3.0.CO;2-P
18. Freeman, G.J., G.S. Gray, C.D. Gimmi, D.B. Lombard, L.J. Zhou, M. White, J.D. Fingeroth, J.G. Gribben, and L.M. Nadler. 1991. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174: 625-631. http://dx.doi.org/10.1084/jem.174.3.625
19. Freeman, G.J., D.B. Lombard, C.D. Gimmi, S.A. Brod, K. Lee, J.C. Laning, D.A. Hafler, M.E. Dorf, G.S. Gray, H. Reiser, et al. 1992. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J. Immunol. 149:3795-3801.
20. Freeman, G.J., F. Borriello, R.J. Hodes, H. Reiser, J.G. Gribben, J.W. Ng, J. Kim, J.M. Goldberg, K. Hathcock, G. Laszlo, et al. 1993. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178: 2185-2192. http://dx.doi.org/10.1084/jem.178.6.2185
21. + regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J. Exp. Med. 206: 421-434. http://dx.doi.org/10.1084/jem.20081811
22. Gough, S.C., L.S. Walker, and D.M. Sansom. 2005. CTLA4 gene polymorphism and autoimmunity. Immunol. Rev. 204: 102-115. http://dx.doi .org/10.1111/j.0105-2896.2005.00249.x
23. Greenwald, R.J., M.A. Oosterwegel, D. van der Woude, A. Kubal, D.A. Mandelbrot, V.A. Boussiotis, and A.H. Sharpe. 2002. CTLA-4 regulates cell cycle progression during a primary immune response. Eur. J. Immunol. 32: 366-373. http://dx.doi.org/10.1002/1521-4141(200202)32:2<366:AID-IMMU366>3.0.CO;2-5
24. Harper, K., C. Balzano, E. Rouvier, M.G. Mattéi, M.F. Luciani, and P. Golstein. 1991. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J. Immunol. 147:1037-1044.
25. Hodi, F.S., S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J.C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723. http://dx.doi.org/10.1056/NEJMoa1003466
26. Ise, W., M. Kohyama, K.M. Nutsch, H.M. Lee, A. Suri, E.R. Unanue, T.L. Murphy, and K.M. Murphy. 2010. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat. Immunol. 11: 129-135. http://dx.doi.org/10.1038/ni.1835
27. Jain, N., H. Nguyen, C. Chambers, and J. Kang. 2010. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc. Natl. Acad. Sci. USA. 107: 1524-1528. http://dx.doi.org/10.1073/pnas.0910341107
28. Karandikar, N.J., C.L. Vanderlugt, T.L. Walunas, S.D. Miller, and J.A. Bluestone. 1996. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184: 783-788. http://dx.doi.org/10.1084/jem.184.2.783
29. Kocak, E., K. Lute, X. Chang, K.F. May Jr., K.R. Exten, H. Zhang, S.F. Abdessalam, A.M. Lehman, D. Jarjoura, P. Zheng, and Y. Liu. 2006. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 66: 7276-7284. http://dx.doi.org/10.1158/0008-5472.CAN-05-2128
30. Kong, K.F., G. Fu, Y. Zhang, T. Yokosuka, J. Casas, A.J. Canonigo-Balancio, S. Becart, G. Kim, J.R. Yates III, M. Kronenberg, et al. 2014. Protein kinase C-η controls CTLA-4-mediated regulatory T cell function. Nat. Immunol. 15: 465-472. http://dx.doi.org/10.1038/ni.2866
31. Krummel, M.F., and J.P. Allison. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183: 2533-2540. http://dx.doi.org/10.1084/jem.183.6.2533
32. Lee, K.M., E. Chuang, M. Griffin, R. Khattri, D.K. Hong, W. Zhang, D. Straus, L.E. Samelson, C.B. Thompson, and J.A. Bluestone. 1998. Molecular basis of T cell inactivation by CTLA-4. Science. 282: 2263-2266. http://dx.doi.org/10.1126/science.282.5397.2263
33. Lee, Y., A. Awasthi, N. Yosef, F.J. Quintana, S. Xiao, A. Peters, C. Wu, M. Kleinewietfeld, S. Kunder, D.A. Hafler, et al. 2012. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 13: 991-999. http://dx.doi.org/10.1038/ni.2416
34. Linsley, P.S., W. Brady, M. Urnes, L.S. Grosmaire, N.K. Damle, and J.A. Ledbetter. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174: 561-569. http://dx.doi.org/10.1084/jem .174.3.561
35. Linsley, P.S., J.L. Greene, P. Tan, J. Bradshaw, J.A. Ledbetter, C. Anasetti, and N.K. Damle. 1992. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176: 1595-1604. http://dx.doi.org/10.1084/jem.176.6.1595
36. Liu, Z., K. Geboes, P. Hellings, P. Maerten, H. Heremans, P. Vandenberghe, L. Boon, P. van Kooten, P. Rutgeerts, and J.L. Ceuppens. 2001. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis. J. Immunol. 167: 1830-1838. http://dx.doi.org/10.4049/jimmunol.167.3.1830
37. Liu, S.M., A.P. Sutherland, Z. Zhang, D.B. Rainbow, F.J. Quintana, A.M. Paterson, A.H. Sharpe, M. Oukka, L.S. Wicker, and V.K. Kuchroo. 2012. Overexpression of the Ctla-4 isoform lacking exons 2 and 3 causes autoimmunity. J. Immunol. 188: 155-162. http://dx.doi.org/10.4049/ jimmunol.1102042
38. Marengère, L.E., P. Waterhouse, G.S. Duncan, H.W. Mittrücker, G.S. Feng, and T.W. Mak. 1996. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science. 272: 1170-1173. http://dx.doi.org/10.1126/science.272.5265.1170
39. Metzler, B., C. Burkhart, and D.C. Wraith. 1999. Phenotypic analysis of CTLA-4 and CD28 expression during transient peptide-induced T cell activation in vivo. Int. Immunol. 11: 667-675. http://dx.doi.org/10.1093/intimm/11.5.667
40. + T cells. J. Exp. Med. 212: 1125-1137. http://dx.doi.org/10.1084/jem.20142237
41. Olsson, C., K. Riesbeck, M. Dohlsten, and E. Michaëlsson. 1999. CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T cell blasts. J. Biol. Chem. 274: 14400-14405. http://dx.doi.org/10.1074/jbc.274.20.14400
42. + natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl. Acad. Sci. USA. 105: 10113-10118. http://dx.doi.org/10.1073/pnas.0711106105
43. Perrin, P.J., J.H. Maldonado, T.A. Davis, C.H. June, and M.K. Racke. 1996. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 157:1333-1336.
44. + thymocytes by T cell receptor-induced apoptosis requires a costimulatory signal that can be provided by CD28. J. Exp. Med. 179: 709-713. http://dx.doi.org/10.1084/jem.179.2.709
45. + thymocytes by two distinct mechanisms differing in their requirement for CD28 costimulation:implications for negative selection in the thymus. J. Exp. Med. 186: 1911-1922. http://dx.doi.org/10.1084/jem.186.11.1911
46. Qureshi, O.S., Y. Zheng, K. Nakamura, K. Attridge, C. Manzotti, E.M. Schmidt, J. Baker, L.E. Jeffery, S. Kaur, Z. Briggs, et al. 2011. Transendocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 332: 600-603. http://dx.doi.org/10.1126/science.1202947
47. +regulatory cells that control intestinal inflammation. J. Exp. Med. 192: 295-302. http://dx.doi.org/10.1084/jem.192.2.295
48. + regulatory T cells abrogates their function in vivo. J. Immunol. 177: 4376-4383. http://dx.doi.org/10.4049/jimmunol.177.7.4376
49. Robert, C., L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbe, J.F. Baurain, A. Testori, J.J. Grob, et al. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364: 2517-2526. http://dx.doi.org/10.1056/NEJMoa1104621
50. Rubtsov, Y.P., R.E. Niec, S. Josefowicz, L. Li, J. Darce, D. Mathis, C. Benoist, and A.Y. Rudensky. 2010. Stability of the regulatory T cell lineage in vivo. Science. 329: 1667-1671. http://dx.doi.org/10.1126/science.1191996
51. Sage, P.T., A.M. Paterson, S.B. Lovitch, and A.H. Sharpe. 2014. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity. 41: 1026-1039. http://dx.doi.org/10.1016/j.immuni.2014.12.005
52. + immunoregulatory T cells that control autoimmune diabetes. Immunity. 12: 431-440. http://dx.doi.org/10.1016/S1074-7613(00)80195-8
53. Samy, E.T., K.M. Wheeler, R.J. Roper, C. Teuscher, and K.S. Tung. 2008. Cutting edge: Autoimmune disease in day 3 thymectomized mice is actively controlled by endogenous disease-specific regulatory T cells. J. Immunol. 180: 4366-4370. http://dx.doi.org/10.4049/jimmunol.180.7.4366
54. Scalapino, K.J., and D.I. Daikh. 2008. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol. Rev. 223: 143-155. http://dx.doi.org/10.1111/j.1600-065X.2008.00639.x
55. Schmidt, E.M., C.J. Wang, G.A. Ryan, L.E. Clough, O.S. Qureshi, M. Goodall, A.K. Abbas, A.H. Sharpe, D.M. Sansom, and L.S. Walker. 2009. Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J. Immunol. 182: 274-282. http://dx.doi.org/10.4049/jimmunol.182.1.274
56. Selby, M.J., J.J. Engelhardt, M. Quigley, K.A. Henning, T. Chen, M. Srinivasan, and A.J. Korman. 2013. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 1: 32-42. http://dx.doi.org/10.1158/2326-6066.CIR-13-0013
57. Sharpe, A.H., and G.J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2: 116-126. http://dx.doi.org/10.1038/nri727
58. Simpson, T.R., F. Li, W. Montalvo-Ortiz, M.A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J.Y. Henry, H. Yagita, J.D. Wolchok, et al. 2013. Fc-dependent depletion of tumor-infiltrating regulatory T cells codefines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210: 1695-1710. http://dx.doi.org/10.1084/jem.20130579
59. Sobel, R.A., V.K. Tuohy, Z.J. Lu, R.A. Laursen, and M.B. Lees. 1990. Acute experimental allergic encephalomyelitis in SJL/J mice induced by a synthetic peptide of myelin proteolipid protein. J. Neuropathol. Exp. Neurol. 49: 468-479. http://dx.doi.org/10.1097/00005072-199009000-00002
60. Tai, X., M. Cowan, L. Feigenbaum, and A. Singer. 2005. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat. Immunol. 6: 152-162. http://dx.doi.org/10.1038/ni1160
61. + T cells. Blood. 119: 5155-5163. http://dx.doi.org/10.1182/blood-2011-11-388918
62. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192: 303-310. http://dx.doi.org/10.1084/jem.192.2.303
63. Takahashi, S., H. Kataoka, S. Hara, T. Yokosuka, K. Takase, S. Yamasaki, W. Kobayashi, Y. Saito, and T. Saito. 2005. In vivo overexpression of CTLA-4 suppresses lymphoproliferative diseases and thymic negative selection. Eur. J. Immunol. 35: 399-407. http://dx.doi.org/10.1002/eji.200324746
64. + regulatory T cells. J. Immunol. 171: 3348-3352. http://dx.doi.org/10.4049/jimmunol.171.7.3348
65. + regulatory T cell function. Eur. J. Immunol. 34: 2996-3005. http://dx.doi .org/10.1002/eji.200425143
66. Tivol, E.A., F. Borriello, A.N. Schweitzer, W.P. Lynch, J.A. Bluestone, and A.H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 3: 541-547. http://dx.doi.org/10.1016/1074-7613(95)90125-6
67. Ueda, H., J.M. Howson, L. Esposito, J. Heward, H. Snook, G. Chamberlain, D.B. Rainbow, K.M. Hunter, A.N. Smith, G. Di Genova, et al. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 423: 506-511. http://dx.doi.org/10.1038/nature01621
68. + T-regulatory cells protects CTLA-4-deficient mice from CNS autoimmune disease. Proc. Natl. Acad. Sci. USA. 106: 3306-3311. http://dx.doi.org/10.1073/pnas .0803186106
69. Verhagen, J., R. Genolet, G.J. Britton, B.J. Stevenson, C.A. Sabatos-Peyton, J. Dyson, I.F. Luescher, and D.C. Wraith. 2013. CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire. Proc. Natl. Acad. Sci. USA. 110:E221-E230. http://dx.doi.org/10.1073/pnas.1208573110
70. Wagner, D.H. Jr., J. Hagman, P.S. Linsley, W. Hodsdon, J.H. Freed, and M.K. Newell. 1996. Rescue of thymocytes from glucocorticoid-induced cell death mediated by CD28/CTLA-4 costimulatory interactions with B7-1/B7-2. J. Exp. Med. 184: 1631-1638. http://dx.doi.org/10.1084/jem.184.5.1631
71. Walker, L.S. 2013. Treg and CTLA-4: two intertwining pathways to immune tolerance. J. Autoimmun. 45: 49-57. http://dx.doi.org/10.1016/j.jaut.2013.06.006
72. Walunas, T.L., C.Y. Bakker, and J.A. Bluestone. 1996. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183: 2541-2550. http://dx.doi.org/10.1084/jem.183.6.2541
73. Wang, X., A. Spandidos, H. Wang, and B. Seed. 2012. PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res. 40(D1):D1144-D1149. http://dx.doi.org/10.1093/nar/gkr1013
74. Waterhouse, P., J.M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K.P. Lee, C.B. Thompson, H. Griesser, and T.W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 270: 985-988. http://dx.doi.org/10.1126/science.270.5238.985
75. + regulatory T cell function. Science. 322: 271-275. http://dx.doi .org/10.1126/science.1160062
76. Workman, C.J., L.W. Collison, M. Bettini, M.R. Pillai, J.E. Rehg, and D.A. Vignali. 2011. In vivo Treg suppression assays. Methods Mol. Biol. 707: 119-156. http://dx.doi.org/10.1007/978-1-61737-979-6_9
77. Wu, Y., M. Borde, V. Heissmeyer, M. Feuerer, A.D. Lapan, J.C. Stroud, D.L. Bates, L. Guo, A. Han, S.F. Ziegler, et al. 2006. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 126: 375-387. http://dx.doi.org/10.1016/j.cell.2006.05.042
78. Yang, S., N. Fujikado, D. Kolodin, C. Benoist, and D. Mathis. 2015. Immune tolerance. Regulatory T cells generated early in life play a distinct role in maintaining self-tolerance. Science. 348:589-594 (Epub ahead of print). http://dx.doi.org/10.1126/science.aaa7017
79. Yosef, N., A.K. Shalek, J.T. Gaublomme, H. Jin, Y. Lee, A. Awasthi, C.Wu, K. Karwacz, S. Xiao, M. Jorgolli, et al. 2013. Dynamic regulatory network controlling TH17 cell differentiation. Nature. 496: 461-468. http://dx.doi.org/10.1038/nature11981
80. Zhang, R., A. Huynh, G. Whitcher, J. Chang, J.S. Maltzman, and L.A. Turka. 2013. An obligate cell-intrinsic function for CD28 in Tregs. J. Clin.Invest. 123:580-593.
81. Zheng, Y., S.Z. Josefowicz, A. Kas, T.T. Chu, M.A. Gavin, and A.Y. Rudensky. 2007. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 445: 936-940. http://dx.doi .org/10.1038/nature05563